Cargando…

Interleukin gene delivery for cancer gene therapy: In vitro and in vivo studies

Cytokine-mediated cancer therapy has the potential to enhance immunotherapeutic approaches and cancer elimination plans through the endowing of the immune system by providing improved anticancer immunity. Despite the encouraging pioneer studies on interleukins (ILs), the influence of ILs-originated...

Descripción completa

Detalles Bibliográficos
Autores principales: Azimifar, Mohammad Amin, Hashemi, Maryam, Babaei, Nahid, Salmasi, Zahra, Doosti, Abbas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mashhad University of Medical Sciences 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9869882/
https://www.ncbi.nlm.nih.gov/pubmed/36742134
http://dx.doi.org/10.22038/IJBMS.2022.66890.14668
_version_ 1784876861174579200
author Azimifar, Mohammad Amin
Hashemi, Maryam
Babaei, Nahid
Salmasi, Zahra
Doosti, Abbas
author_facet Azimifar, Mohammad Amin
Hashemi, Maryam
Babaei, Nahid
Salmasi, Zahra
Doosti, Abbas
author_sort Azimifar, Mohammad Amin
collection PubMed
description Cytokine-mediated cancer therapy has the potential to enhance immunotherapeutic approaches and cancer elimination plans through the endowing of the immune system by providing improved anticancer immunity. Despite the encouraging pioneer studies on interleukins (ILs), the influence of ILs-originated therapeutics is still restricted by a class of potent immunoregulatory cytokines, systemic dose-limiting toxicities, ILs pleiotropy, and administration issues. During previous years, the area of transferring genes encoding immunostimulatory ILs was fundamentally widened to overcome these challenges and expedite ILs-based tumor regression. Numerous viral and non-viral delivery systems are currently available to act as crucial elements of the gene therapy toolbox. Moreover, cell-based cancer therapies are recruiting MSCs in the role of versatile gene delivery platforms to design one of the promising therapeutic approaches. These formulated gene carrier systems can provide possible alternatives to diminish dose-limiting adverse effects, promote administration, and enhance the therapeutic activity of ILs-derived treatment modalities in cancer treatment. This review provides a discussion on the advances of ILs gene delivery systems while focusing on the developing platforms in preclinical cancer immunogene therapy studies.
format Online
Article
Text
id pubmed-9869882
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Mashhad University of Medical Sciences
record_format MEDLINE/PubMed
spelling pubmed-98698822023-02-02 Interleukin gene delivery for cancer gene therapy: In vitro and in vivo studies Azimifar, Mohammad Amin Hashemi, Maryam Babaei, Nahid Salmasi, Zahra Doosti, Abbas Iran J Basic Med Sci Review Article Cytokine-mediated cancer therapy has the potential to enhance immunotherapeutic approaches and cancer elimination plans through the endowing of the immune system by providing improved anticancer immunity. Despite the encouraging pioneer studies on interleukins (ILs), the influence of ILs-originated therapeutics is still restricted by a class of potent immunoregulatory cytokines, systemic dose-limiting toxicities, ILs pleiotropy, and administration issues. During previous years, the area of transferring genes encoding immunostimulatory ILs was fundamentally widened to overcome these challenges and expedite ILs-based tumor regression. Numerous viral and non-viral delivery systems are currently available to act as crucial elements of the gene therapy toolbox. Moreover, cell-based cancer therapies are recruiting MSCs in the role of versatile gene delivery platforms to design one of the promising therapeutic approaches. These formulated gene carrier systems can provide possible alternatives to diminish dose-limiting adverse effects, promote administration, and enhance the therapeutic activity of ILs-derived treatment modalities in cancer treatment. This review provides a discussion on the advances of ILs gene delivery systems while focusing on the developing platforms in preclinical cancer immunogene therapy studies. Mashhad University of Medical Sciences 2023-02 /pmc/articles/PMC9869882/ /pubmed/36742134 http://dx.doi.org/10.22038/IJBMS.2022.66890.14668 Text en https://creativecommons.org/licenses/by/3.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (http://creativecommons.org/licenses/by/3.0/ (https://creativecommons.org/licenses/by/3.0/) ) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Azimifar, Mohammad Amin
Hashemi, Maryam
Babaei, Nahid
Salmasi, Zahra
Doosti, Abbas
Interleukin gene delivery for cancer gene therapy: In vitro and in vivo studies
title Interleukin gene delivery for cancer gene therapy: In vitro and in vivo studies
title_full Interleukin gene delivery for cancer gene therapy: In vitro and in vivo studies
title_fullStr Interleukin gene delivery for cancer gene therapy: In vitro and in vivo studies
title_full_unstemmed Interleukin gene delivery for cancer gene therapy: In vitro and in vivo studies
title_short Interleukin gene delivery for cancer gene therapy: In vitro and in vivo studies
title_sort interleukin gene delivery for cancer gene therapy: in vitro and in vivo studies
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9869882/
https://www.ncbi.nlm.nih.gov/pubmed/36742134
http://dx.doi.org/10.22038/IJBMS.2022.66890.14668
work_keys_str_mv AT azimifarmohammadamin interleukingenedeliveryforcancergenetherapyinvitroandinvivostudies
AT hashemimaryam interleukingenedeliveryforcancergenetherapyinvitroandinvivostudies
AT babaeinahid interleukingenedeliveryforcancergenetherapyinvitroandinvivostudies
AT salmasizahra interleukingenedeliveryforcancergenetherapyinvitroandinvivostudies
AT doostiabbas interleukingenedeliveryforcancergenetherapyinvitroandinvivostudies